Arcturus Therapeutics (ARCT) Stock Forecast, Price & News

Arcturus Therapeutics (NASDAQ:ARCT) Frequently Asked Questions

Is Arcturus Therapeutics a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last twelve months. There are currently 2 sell ratings, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Arcturus Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARCT, but not buy additional shares or sell existing shares.
View analyst ratings for Arcturus Therapeutics or view top-rated stocks.

Are investors shorting Arcturus Therapeutics?

Arcturus Therapeutics saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 3,050,000 shares, an increase of 24.0% from the April 15th total of 2,460,000 shares. Based on an average daily trading volume, of 602,100 shares, the days-to-cover ratio is presently 5.1 days. Currently, 13.4% of the shares of the stock are sold short.
View Arcturus Therapeutics' Short Interest.

When is Arcturus Therapeutics' next earnings date?

Arcturus Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Arcturus Therapeutics.

How were Arcturus Therapeutics' earnings last quarter?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) released its quarterly earnings data on Monday, May, 9th. The biotechnology company reported ($1.94) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.44) by $0.50. Arcturus Therapeutics had a negative trailing twelve-month return on equity of 64.94% and a negative net margin of 1,282.62%. During the same period last year, the company earned ($2.15) earnings per share.
View Arcturus Therapeutics' earnings history.

What price target have analysts set for ARCT?

7 analysts have issued 1-year price objectives for Arcturus Therapeutics' stock. Their forecasts range from $17.00 to $105.00. On average, they anticipate Arcturus Therapeutics' stock price to reach $42.38 in the next twelve months. This suggests a possible upside of 138.5% from the stock's current price.
View analysts' price targets for Arcturus Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Arcturus Therapeutics' key executives?

Arcturus Therapeutics' management team includes the following people:

• Mr. Joseph E. Payne M.Sc., Founder, Pres, CEO & Director (Age 50, Pay $950k)
• Dr. Padmanabh Chivukula, Founder, Chief Scientific Officer, COO & Sec. (Age 43, Pay $640k)
• Mr. Andrew H. Sassine MBA, CFO & Director (Age 58, Pay $640k)
• Mr. Lance Kurata, Chief Legal Officer
• Dr. Steven George Hughes M.B.A., M.D., Strategic Clinical Advisor & Member of Scientific Advisory Board (Age 54, Pay $664k)
• Mr. Keith C. Kummerfeld CPA, VP of Fin. & Corp. Controller
• Dr. Dushyant B. Varshney Ph.D., Exec. VP & Chief Technology Officer
• Mr. Kevin T. Skol, Sr. VP of Bus. Devel. & Alliance Management
• Dr. Kelly A. Lindert M.D., Chief Devel. Officer of Vaccines

What is Joe Payne's approval rating as Arcturus Therapeutics' CEO?

9 employees have rated Arcturus Therapeutics CEO Joe Payne on Glassdoor.com. Joe Payne has an approval rating of 90% among Arcturus Therapeutics' employees.

Who are some of Arcturus Therapeutics' key competitors?

Some companies that are related to Arcturus Therapeutics include Amphastar Pharmaceuticals (AMPH), Aurinia Pharmaceuticals (AUPH), Travere Therapeutics (TVTX), HUTCHMED (HCM), Xenon Pharmaceuticals (XENE), ChemoCentryx (CCXI), Supernus Pharmaceuticals (SUPN), Emergent BioSolutions (EBS), Ligand Pharmaceuticals (LGND), Taro Pharmaceutical Industries (TARO), Xencor (XNCR), BELLUS Health (BLUSF), Sierra Oncology (SRRA), Arcus Biosciences (RCUS) and 23andMe (ME).
View all of ARCT's competitors.

What other stocks do shareholders of Arcturus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and Sanofi (SNY).

What is Arcturus Therapeutics' stock symbol?

Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT."

Who are Arcturus Therapeutics' major shareholders?

Arcturus Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Federated Hermes Inc. (14.24%), State Street Corp (12.18%), ARK Investment Management LLC (9.04%), BlackRock Inc. (6.42%), Sumitomo Mitsui Trust Holdings Inc. (5.32%) and Nikko Asset Management Americas Inc. (5.31%). Company insiders that own Arcturus Therapeutics stock include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Pad Chivukula and Ultragenyx Pharmaceutical Inc.
View institutional ownership trends for Arcturus Therapeutics.

Which major investors are selling Arcturus Therapeutics stock?

ARCT stock was sold by a variety of institutional investors in the last quarter, including ACT Capital Management LLC, ARK Investment Management LLC, Citigroup Inc., BlackRock Inc., Bank Julius Baer & Co. Ltd Zurich, Jane Street Group LLC, Connor Clark & Lunn Investment Management Ltd., and JPMorgan Chase & Co.. Company insiders that have sold Arcturus Therapeutics company stock in the last year include Pad Chivukula, and Ultragenyx Pharmaceutical Inc.
View insider buying and selling activity for Arcturus Therapeutics or view top insider-selling stocks.

Which major investors are buying Arcturus Therapeutics stock?

ARCT stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Dimensional Fund Advisors LP, UBS Group AG, Federated Hermes Inc., Integral Health Asset Management LLC, Los Angeles Capital Management LLC, Nikko Asset Management Americas Inc., and Sumitomo Mitsui Trust Holdings Inc.. Company insiders that have bought Arcturus Therapeutics stock in the last two years include Andy Sassine, Joseph E Payne, and Keith C Kummerfeld.
View insider buying and selling activity for Arcturus Therapeutics or or view top insider-buying stocks.

How do I buy shares of Arcturus Therapeutics?

Shares of ARCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcturus Therapeutics' stock price today?

One share of ARCT stock can currently be purchased for approximately $17.77.

How much money does Arcturus Therapeutics make?

Arcturus Therapeutics has a market capitalization of $469.48 million and generates $12.40 million in revenue each year. The biotechnology company earns $-203.70 million in net income (profit) each year or ($7.53) on an earnings per share basis.

How many employees does Arcturus Therapeutics have?

Arcturus Therapeutics employs 177 workers across the globe.

What is Arcturus Therapeutics' official website?

The official website for Arcturus Therapeutics is www.arcturusrx.com.

How can I contact Arcturus Therapeutics?

Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at (858) 900-2660 or via email at [email protected].